SEC Form 4 · accession 0001193125-26-316457
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard W Robin
Officer — President & CEO · Director
Period of report
Jul 24, 2026
Accepted (ET)
Jul 24, 2026 · 6:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000906709
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | $15.15 | Jul 24, 2026 | A | 57,200 | A | — | Dec 12, 2032 | Common Stock | 57,200 | 57,200 | D |
Explanation of responses
- F1These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.
- F2The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).